Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer

Inclusion Criteria:

• Breast cancer patients diagnosed by pathology;

• EOOG score is 0 or 1;

• The age range for enrollment is between 18 and 75 years old; ④ Acceptchemotherapy regimens based on taxane drugs (alone or in combination); ⑤ Previously received taxane chemotherapy for more than 6 months; ⑥ According to the National Cancer Institute (NCI) Common Terminology forAdverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higherfor more than 2 weeks; ⑦ Voluntarily participate in this clinical trial and sign the informedconsent form;

• Accept regular follow-up visits; ⑨ There is complete pathologicaldata available.

Exclusion Criteria:

• Non breast cancer patients;

• Received electroacupuncture treatment within 6 months prior to the start of thestudy;

• Patients who experience intolerable toxic side effects during standarddose chemotherapy and terminate the chemotherapy cycle;

• Prior to enrollment, there was a history of peripheral neuropathy;

• Unstable heart disease or myocardial infarction within the first 6 months of the study; ⑥ Active skin diseases or surface skin ulcers or infections thatcannot tolerate electroacupuncture treatment; ⑦ Uncontrolled epilepsy patients with uncontrolled seizures; ⑧ Merge with other malignant tumor patients; ⑨ Pregnancy and lactation period; ⑩ Refusal to join clinical trial patients